Core Viewpoint - Kangchen Pharmaceutical (01681) experienced a significant stock price increase of over 7%, reaching a new high of 14.59 HKD since its listing, following the release of its interim financial results [1] Financial Performance - The company reported a revenue of 1.569 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 23.7% [1] - The profit attributable to equity shareholders was 498 million RMB, reflecting a year-on-year growth of 24.6% [1] - Basic earnings per share were reported at 0.59 RMB, with an interim dividend proposed at 0.33 HKD per share, up from 0.30 HKD in the same period last year [1] Product Performance - Sales from the nephrology product line grew approximately 28.0% compared to the same period last year, with Uremic Clear Granules (尿毒清) remaining the company's flagship product and maintaining its market leadership [1] - The pediatric and women's health product line saw a sales increase of about 17.5% year-on-year, becoming the second largest revenue contributor for the company [1]
港股异动 | 康臣药业(01681)午后涨超7%创新高 上半年纯利同比增长24.6% 中期息0.33港元